Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

RB and cell cycle progression

Abstract

The Rb protein is a tumor suppressor, which plays a pivotal role in the negative control of the cell cycle and in tumor progression. It has been shown that Rb protein (pRb) is responsible for a major G1 checkpoint, blocking S-phase entry and cell growth. The retinoblastoma family includes three members, Rb/p105, p107 and Rb2/p130, collectively referred to as ‘pocket proteins’. The pRb protein represses gene transcription, required for transition from G1 to S phase, by directly binding to the transactivation domain of E2F and by binding to the promoter of these genes as a complex with E2F. pRb represses transcription also by remodeling chromatin structure through interaction with proteins such as hBRM, BRG1, HDAC1 and SUV39H1, which are involved in nucleosome remodeling, histone acetylation/deacetylation and methylation, respectively. Loss of pRb functions may induce cell cycle deregulation and so lead to a malignant phenotype. Gene inactivation of pRB through chromosomal mutations is one of the principal reasons for retinoblastoma tumor development. Functional inactivation of pRb by viral oncoprotein binding is also shown in many neoplasias such as cervical cancer, mesothelioma and AIDS-related Burkitt's lymphoma.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1

References

  • Adams PD, KAelin WG . (1995). Semin Cancer Biol 6: 99–108.

  • Baldi A, Boccia V, Claudio PP, De Luca A, Giordano A . (1996). Proc Natl Acad Sci 93: 4629–4632.

  • Bignon YJ, Rio P . (1993). Bull Cancer 80: 704–712.

  • Caputi M, Russo G, Esposito V, Mancini A, Giordano A . (2005). J Cell Physiol 205: 319–327.

  • Chen D, Livne-bar I, Vanderluit JL, Slack RS, Agochiya M, Bremner R . (2004). Cancer Cell 5: 539–551.

  • Cinti C, Giordano A . (2000). Emerg Ther Targets 4: 765–783.

  • Cinti C, Leoncini L, Nwongo A . (2000). Am J Pathol 156: 751–760.

  • Claudio PP, De Luca A, Howard CM, Baldi A, Firpo Ej, Koff A et al. (1996). Cancer Res 56: 2003–2008.

  • Claudio PP, Tonin T, Giordano A . (2002). Genome 3: 3012.

  • Claudio PP, Howard CM, Fu Y . (2000). Cancer Res 60: 8–12.

  • Cobrinik D . (2005). Oncogene 24: 2796–2809.

  • Cobrinik D, White P, Peeper Ds, Jacks T, Weinberg RA . (1993). Genes dev 7: 2393–2404.

  • Condorelli G, Giordano A . (1997). J Cell Biochem 67: 423–431.

  • Dahiya A, Wong S, Gonzalo S, Gavin M, Dean DC . (2001). Mol Cell 8: 557–569.

  • De Falco G, Bellan C, Lazzi S, Caludio P, La Sala D, Cinti C et al. (2003). Oncogene 22: 6214–6219.

  • De Falco G, Comes F, Simone C . (2006). Oncogene, review in this issue.

  • De Luca A, MacLachlan JK, Bagella L, Dean C, Howard CM, Claudio PP et al. (1997). J Biol Chem 272: 20971–20974.

  • De La Luna S, Burden Mj, Lee C-W, La Thangue NB . (1996). J Cell Sci 109: 2443–2452.

  • Dimova DK, Dyson N . (2005). Oncogene 44: 30–33.

  • Dingwall C, LAskey RA . (1991). Trends Biol Sci 16: 478–481.

  • DiStefano L, Jensen MR, Helin K . (2003). EMBO J 22: 6289–6298.

  • Dowdy SF, Hinds PW, Louis K, Reed SI, Arnold A, Weinberg RA . (1993). Cell 73: 499–511.

  • Dunn JM, Phillips RA, Becker AJ, Gallie BL . (1988). Science 241: 1797–1800.

  • Dyson N . (2002). Curr Opin Cell Biol 14: 684–691.

  • Dyson N . (1998). Genes Dev 12: 2245–2262.

  • Fang W, Mori T, Cobrinik D . (2002). Oncogene 21: 5557–5565.

  • Gallo G, Giordano A . (2005). J Cell Phys 2: 176–181.

  • Gagrica S, Hauser S, Kolfschoten I, Osterloh L, Agami R, Gaubatz S . (2004). EMBO J 23: 4627–4638.

  • Gaubatz S, Lindeman GJ, Ishida S, Jakoi L, Nevins JR, Livingston DM et al. (2000). Mol Cell 6: 729–735.

  • Geng Y, Yu Q, Whoriskey W, Dick F, Tsai KY, Ford HI et al. (2001). Proc Natl Acad Sci USA 98: 13138–13143.

  • Harbour JW, Dean DC . (2000). Cell 101: 79–89.

  • Helin K, Herlow E, Fattey A . (1993). Mol Cell Biol 13: 3149–3156.

  • Herrera RE, Tan VP, Williams BO, Makela T, Weinberg RA, Jacks T . (1996). Mol Cell Biol 16: 2402–2407.

  • Hitomi M, Stacey DW . (1999). Curr Biol 19: 1075–1084.

  • Hopnefer R, Mousli M, Garnier JM, Redon R, du Manoir S, Chatton B et al. 2000. Cancer Res 1: 121–128.

  • Hunter T, Pines J . (1994). Cell 79: 573–582.

  • Ichimura K, Hanafusa H, Takimoto H, Ohgama Y, Akagi T, Shimizu K . (2000). Gene 251: 37–43.

  • Jeanblanc M, Mousli M, Hopfner R, Bathami K, Martinet N, Abbady et al. (2005). Oncogene 49: 7337–7345.

  • Jackman M, Firth M, Pines J . (1995). EMBO J 14: 1646–1654.

  • Johnson DG, Schendeider-Broussard R . (1998). Front Biosci 3: D447–D458.

  • Kang H, Cui K, Zhao K . (2004). Mol Cell Biol 24: 1188–1199.

  • Keyomarsi K, Conte Jr D, Toyofuku W, Fox MP . (1995). Oncogene 11: 941–950.

  • Kim YT, Zhao M . (2005). Yonsei Med J 31: 597–613.

  • Knudson AG . (1971). Proc Natl Acad Sci USA 68: 820–823.

  • Lai A, Lee JM, Yang WM, De Caprio JA, Keelin WG et al. (1999). Mol Cell Biol 19: 6632–6641.

  • Lazzi S, Bellan C, De Falco G, Cinti C, Ferrari F et al. (2002). Hum Pathol 33: 723–731.

  • Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K et al. (1992). Nature 359: 288–294.

  • Lee EY, Cam H, Ziebold U, Rayman JB, Lees JA, Dynlacht BD . (2002). Cancer Cell 2: 463–472.

  • Lee JO, Russo AA, Pavletich NP . (1998). Nature 391: 859–865.

  • Lee MH, Williams Bo, Mulligan G . (1996). Genes Dev 16: 1621–1632.

  • Lees W-H, Shew J-Y, Hong FD, Sery TW, Donoso Lees EM, Harlow E . (1993). Mol Cell Biol 2: 1194–1201.

  • Liu H, Dibling B, Spike B, Dirlam A, Macleod K . (2004). Curr Opin Genet Dev 14: 55–64.

  • Ludlow JW, Glendening CL, Livingston DM, DeCarprio JA . (1993). Mol Cell Biol 13: 367–372.

  • Lundberg AS, Weinberg RA . (1999). Eur J Cancer 35: 531–539.

  • Luo RX, Postigo AA, Dean DC . (1998). Cell 92: 463–473.

  • Ma D, Zhou P, Harbour JW . (2003). J Biol Chem 278: 19358–19366.

  • Macaluso M, Montanari M, Cinti C, Giordano A . (2005). Semin Oncol 32: 452–457.

  • Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, LeVillain JP et al. (1998). Nature 391: 601–604.

  • Matsushime H, Roussel MF, Ashmun RA, Sherr CJ . (1991). Cell 65: 701–703.

  • Morkel M, Wenkel J, Bannister AJ, Kouzarides T, Hagemeier C . (1997). Nature 390: 567–568.

  • Mudryj M, Devoto SH, Hiebert SW, Hunter T, Pines J, Nevins JR . (1991). Cell 65: 1243–1253.

  • Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL et al. (2003). Cell 113: 703–716.

  • Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D et al. (2001). Nature 412: 561–565.

  • Ormondroyd E, de la Luna S, La Thangue NB . (1995). Oncogene 11: 1437.

  • Paggi MG, Baldi A, Bonetto F, Giordano A . (1996). J Cell Biochem 62: 418–430.

  • Puri PL, Maclachlan TK, Levrero M, Giordano A . (1999) In: Stein GS, Baserga R, Giordano A, Denhardt DT (eds). The Molecular Basis of Cell Cycle and Growth Control. Wiley: New York, pp 15–79.

    Google Scholar 

  • Qian Y, Luckey C, Horton L, Esser M, Templeton DJ . (1992). Mol Cell Biol 12: 5363–5372.

  • Rayman JB, Takahashi Y, Indjeian VB, Dannenberg JH, Catchpole S, Watson RJ et al. (2002). Genes Dev 16: 933–947.

  • Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid Ren S et al. (2000). Nature 406: 593–599.

  • Ren S, Rollins BJ . (2004). Dev Cell 6: 607–608.

  • Resnitzky D, Gossen M, Buiard H, Reed SI . (1994). Mol Cell Biol 14: 1669–1679.

  • Ross JF, Liu X, Dynlacht BD . (1999). Mol Cell 3: 195–205.

  • Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T . (2003). Nature 424: 223–228.

  • Shao Z, Robbins PD . (1995). Oncogene 10: 221–228.

  • Sherr CJ, Roberts JM . (1995). Genes Dev 9: 1149–1463.

  • Shin EK, Shin A, Paulding C, Schaffhausen B, Yee AS . (1995). Mol Cell Biol 15: 2252–2262.

  • Shirodkar S, Ewen M, DeCaprio JA, Morgan JA, Livingston DM et al. (1992). Cell 68: 157–166.

  • Slagia R, Skarin AT . (1998). J Clin Oncol 16: 1207–1217.

  • Stiegler P, De Luca A, Bagella L, Giordano A . (1998). Cancer Res 58: 5049–5052.

  • Strober BE, Dunaief JL, Guha S, Goff SP . (1996). Mol Cell Biol 16: 1576–1583.

  • Tedesco D, Lukas J, Reed SI . (2002). Genes Dev 16: 2946–2957.

  • Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D . (2001). Mol Cell Biol 21: 6484–6494.

  • Weinberg RA . (1995). Cell 81: 323–330.

  • Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT et al. (2001). Nature 414: 457–462.

  • Young AP, Longmore GD . (2004). Oncogene 23: 2587–2599.

  • Zhang HS, Gavin M, Dahiya A, Postigo AA et al. (2000). Cell 101: 79–89.

Download references

Acknowledgements

This work is supported in part by grants from NIH and Sbarro Health Research Organization. We thank Simone C, De Falco G and Bagella L for their critical comments.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to A Giordano.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Giacinti, C., Giordano, A. RB and cell cycle progression. Oncogene 25, 5220–5227 (2006). https://doi.org/10.1038/sj.onc.1209615

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209615

Keywords

  • Rb
  • cell cycle
  • E2F
  • cancer
  • Rb2/p130
  • tumor suppressor

This article is cited by

Search

Quick links